KPV: what the studies show

KPV and related peptides

KPV is Lys-Pro-Val, a tripeptide corresponding to the terminal sequence of alpha-MSH. Full alpha-MSH, modified tripeptides, and linked KPV dimers are separate molecules. Their clinical studies do not establish efficacy for KPV.

Mouse and cell findings

A 2008 study administered KPV in drinking water to mice with chemically induced colitis and reported less intestinal inflammation. Mouse colitis findings do not establish remission or symptom relief in people with inflammatory bowel disease.

A separate laboratory study exposed immortalised human bronchial epithelial cells to KPV and found reduced stimulated inflammatory signaling. The human-derived cells were studied outside the body. No patients with airway disease received treatment in that experiment.

Formulation and clinical evidence

No FDA-approved product was identified. A clinical trial would need a formulation with defined purity and terminal chemistry. Mouse oral exposure cannot establish absorption from a human capsule, and bronchial-cell exposure does not validate a skin cream.

A controlled human study using a characterized KPV formulation and meaningful clinical outcomes is still needed. Record the terminal chemistry and salt form when comparing research materials.